Skip to main content
Premium Trial:

Request an Annual Quote

T2 Biosystems Preliminary Q4 Revenues up 67 Percent, Firm Announces CEO Transition

NEW YORK – T2 Biosystems announced on Thursday that its preliminary 2019 fourth quarter revenues increased 67 percent year over year.

The Lexington, Massachusetts-based firm also said that John Sperzel has assumed the position of president and CEO of T2 Biosystems as of January 8, 2020. He replaces John McDonough in both roles.

Lastly, the company announced an exclusive distribution deal for its tests in Israel.

For the three months ended December 31, 2019, T2 Biosystems saw revenues of approximately $3 million, which would be up from $1.8 million in Q4 2018. The Wall Street consensus is for $3.7 million in revenues for the recently completed quarter.

Product revenues grew 15 percent year over year to $1.5 million, while research and grants contributed $1.5 million in revenues, T2 Bio said. 

In the quarter, the firm secured contracts for 10 instruments, and received CE mark for its T2 Resistance Panel product which detects 13 genes conferring antimicrobial resistance directly from whole blood.

It also raised $4.8 million net proceeds from the sale of 3.8 million shares through its at-the-market facility, and has not utilized its $30.0 million equity credit line, it said.

T2 Biosystems finished the quarter with cash and cash equivalents of $11.0 million.

"We ended the year with positive momentum in our business, with the addition of new customers and expansion of patient testing at existing customers, a clear sign that the value of our products is being realized," said McDonough, now T2Biosystem's non-executive chairman,  in a statement.

Sperzel, who is now head of the company, was previously the CEO of Chembio Diagnostics.

The company also said that it signed a distribution agreement with an undisclosed partner to introduce the T2 Resistance, T2Bacteria, and T2Candida panels in Israel, which has more than 40 target hospitals. T2 Biosystem's technology is now available in 36 countries outside the US, it added.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.